Nuformix plc (LON:NFX – Get Free Report) traded down 10% during mid-day trading on Tuesday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). 417,744 shares were traded during trading, a decline of 96% from the average session volume of 10,412,084 shares. The stock had previously closed at GBX 0.05 ($0.00).
Nuformix Stock Up 10.0 %
The business’s fifty day simple moving average is GBX 0.05 and its two-hundred day simple moving average is GBX 0.11. The company has a market cap of £450,620.50, a PE ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- Top Stocks Investing in 5G Technology
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Best Aerospace Stocks Investing
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- What Are the U.K. Market Holidays? How to Invest and Trade
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
